Surface logix pharma

Pharma has raised 45 million in equity financing in a round led by Essex Woodlands Health Ventures. Existing investor Ampersand Ventures also. surface Logix closes Series E equity and debt financing Deal Date: Mar-2009; Financing. surface Logix closes first tranche of 42mm Series D round Pharma has raised 45 million in equity financing in a round led by Essex Woodlands Health Ventures. Existing investor Ampersand. surface Logix, and Vertex Pharma Among Recent US Patent Winners Pharma s new CEO is a former Third Rock E-I-R. Logix, Before Surface Logix, he was the president and CEO of Alantos Pharmaceuticals. surface Logix has commenced a company-sponsored Phase I clinical trial for SLx-2101, an oral PDE-5 inhibitor, which is tested for treatment of cardiovascular diseases. surface engineering and nanotechnology company based in Brighton Massachusetts, US, has struck a deal to acquire neighbouring drug developer. surface Logix has presented encouraging Phase 1 trial data for a drug candidate that is being developed for the treatment of abnormal levels of lipids

Pharma s new CEO is a former Third Rock E-I-R. Logix, Before Surface Logix, he was the president and CEO Surface Logix begins trial of SLx-2101.surface. Logix, begins, trial, slx-2101, boston, usa-headquartered Pharma; Professional Services; Regulatory Consultants; Events; News. surface Logix Sorry, we could not find the management team for Surface Logix Surface Logix raises 20M in second financing round. surface. Logix, raises, 20m, second, financing, round Surface Logix developing small-molecule therapeutics for metabolic and cardiovascular disorders raised 15mm. surface Logix announced today that Jim Mahoney, President and Chief Executive Officer, will present an update of

Surface Logix today announced positive results in the Company s Phase 2a clinical trial of SLx-4090 in dyslipidemia high cholesterol and triglyceride levels in

Surface Logix announced today that the Company s lead clinical candidate, SLx-2101, has been selected as one of the Surface Logix, announced today that SLx-4090, a clinical-stage compound, has been selected as one of the top ten most licensable cardiovascular therapeutic Surface Logix, Surface Logix is engaged in discovering and developing small molecule drugs to treat metabolic and cardiovascular diseases.

Surface Logix announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the Surface Logix company data, news, contact details and stock information. surface Logix uses its expertise in biophysical chemistry to create new small.

Pharma; Forest Research Institute; Graceway Pharmaceuticals; Great Lake Drug Development; Integrium; N-Gene Research Laboratories; PFizer; Sciele; Surface Logix. surface Logix got a new CEO on board last fall, and five months later it has nailed down a load of new cash. The Brighton, MA-based biotech company, which. surface Logix, a developer of small molecule drugs to treat metabolic and cardiovascular diseases, has raised over 20 million in a combined equity an Surface Logix, was incorporated in 1999 and is headquartered in Brighton, Massachusetts. 50 Soldiers Field Place. Brighton, MA 02135. United States. surface Logix SLx-4090 Selected Among Top 10 Most Promising Licensing Candidates In Cardiovascular Disease. by PR Newswire Business.

Pharma Launcher: HOME. For Startups. For Venture Capitalists. About Tsaioun managed the ADME programs for NitroMed, and before that, Surface Logix. surface Logix today announced the initiation of a Phase 2a clinical trial for SLx-2101 in patients with secondary Raynaud s disease. surface Logix,: Series E 15M. Posted in I - Series E, Q - 1Q09, R - NORTH EAST, X - Cardiology, X - Metabolism, XX - Pharma Strategy Blog Pharma, from October 2003 through June 2006.surface Logix Appoints Schering Executive, Marc Rubin, D. surface Logix Inc including contact information, career history, news and intelligence. Pharma; Bristol-Myers Squibb; Britannia Pharmaceuticals. surface Logix; UCB; Vectura; Vivus; Warner Chilcott; Zonagen; Products and Services. Pharma. com Contract Research. Nano Terra puts pen to paper in deal for Surface Logix Gold nanoparticles can cut blood supply to tumours. Pharma Board of Directors at FirstString Research Board of Directors Surface Logix. Exclusives. infographic: Hepatitis Top 10 Pharma Firms of 2014; Pharma. surface Logix. SYGNIS Pharma. Synageva BioPharma; Synta Pharmaceuticals; Taiho Pharmaceutical; Takeda Pharmaceutical Company; TapImmune; Thallion. surface Logix. MDS Pharma Services

Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism Surface Logix BNC says nano approach can aid drug-target research. Outsourcing - Pharma. com Surface Logix March 2006 April 2007 1 year 2 months. Bio-world-Networking Clinical, Pharma, Healthcare, Biotech, research Phd s and other professionals. surface Logix. She is also a co-founder and member of the management team of Pharma Launcher, a consortium of pharmaceutical CROs. Pharma. Steven Kates, PhD Vice President. surface Logix, Consensus and Millipore Corporation.

Surface Logix. Outsourcing - Pharma. surface Logix today announced positive results in the Company s Phase 2a clinical trial of SLx-4090 in dyslipidemia high cholesterol.

Pharma s largest market, built upon groundbreaking cardioprevention therapies Surface Logix MTP Inhibitor II Dyslipidemia NX-CP105 Neuronyx Pharma and Surface Logix have raised 45 million and 20 million. Join 100,000+ pharma industry leaders who get FiercePharma via daily. surface Logix. Citius Pharmaceuticals. surface Logix, Consensus and Millipore Corporation. Symphony Pharma Life Sciences 2013.

Pharma. And Pharmacomer Technology platform were originally developed by Surface Logix. Pharma; Forest Research Institute; Graceway Pharmaceuticals; Great Lake Drug Development; Integrium; N-Gene Research Laboratories; PFizer; Sciele; Surface Logix. Pharma. com Contract Research, Manufacturing Clinical Trials. Headlines Bio Developments. Nano Terra puts pen to paper in deal for Surface Logix